BRAF and melanoma: CT-guided fine-needle biopsy demonstrated cells positive for SOX10, MART1, and S100, and negative for cytokeratin, consistent with malignant melanoma. Caris testing (Caris Life Sciences, Irving, USA) demonstrated elevated tumor mutational burden (TMB), BRAF wild-type, and mutations in NRAS, NF1, RAC1, and TERT promoter genes.